Morgan Lewis

STARTUP & ACCELERATE

Preparing To Go Public: Roadmap for Your Early-Stage Startup

April 13, 2023

Bryan S. Keighery and Thurston J. Hamlette

Presenters



Bryan S. Keighery



Thurston J. Hamlette

Morgan Lewis

Before we begin

Tech Support

If you are experiencing technical difficulties, please contact WebEx Tech Support at +1.866.779.3239.

Q&A

The Q&A tab is located near the bottom right hand side of your screen; choose "All Panelists" before clicking "Send."

CLE

We will mention a code at some point during the presentation for attendees who requested CLE. Please make note of that code, and insert it in the pop-up survey that will appear in a new browser tab after you exit out of this webinar. You will receive a Certificate of Attendance from our CLE team in approximately 30 to 45 days.

Audio

The audio will remain quiet until we begin at 12:30pm.

You will hear sound through your computer speakers/headphones automatically. Make sure your speakers are ON and UNMUTED.

To access the audio for by telephone, please click the "phone" icon below your name on the Participants Panel for teleconference information.

Pros of an IPO

- Greater access to capital, of particular importance for compliance with regulatory capital requirements
- Utilizing equity as incentive compensation with liquidity
- Stock value appreciation if stock performs well
- Liquidity for shareholders with equity and potential exit strategy
- More media and public attention (increased prestige)
- Facilitates future acquisitions (with the use of stock)

Pros of an IPO

- Higher valuations than private enterprises (due to liquidity and transparency)
- Enhances ability to benchmark against peers
- Retains future upside potential in business
- Increases opportunities for reducing debt or refinancing
- Improved prospects for attracting and retaining key personnel

Cons of an IPO

- IPO expenses legal, accounting, underwriting, travel and printing costs
- Time-consuming
- Filing and reporting requirements high continuing costs
- Ownership dilution
- Potential stock price manipulation shorts
- Loss of confidentiality
- Significant public scrutiny

Cons of an IPO

- Increased litigation risk
- Limits freedom of management to act required transparency
- Potential loss of control (e.g., dilution of current stockholder interest, risk of takeover)
- Shareholder expectations (e.g., risk of focus on short-term stock price performance versus building long-term value)
- Difficulty recruiting good non-executive directors

Cons of an IPO

- Meeting corporate governance requirements
- Require build out of functions such as investor relations, SEC reporting and human resources
- Acquiring another Federal regulator (the SEC)
- Materially increased regulatory liability for issues

IPO Costs

Figure 4. Summary of going public costs

Average costs by revenue range							
Cost Category	Less than \$100m	\$100m to \$250m	\$250m to \$500m	\$500m to \$1bn	Greater than \$1bn		
Accounting	0.8	1.2	1.3	1.8	1.9		
Legal	1.5	1.9	2.0	3.0	3.0		
Printing	0.3	0.4	0.5	0.6	0.6		
Other*	0.5	0.8	0.9	1.2	1.6		
Underwriting	6.9	10.4	17.4	20.2	27.5		
Total Avg IPO cost	10.1	14.6	22.1	26.5	34.3		

Average costs by proceeds raised								
Cost Category	\$25m to \$100m	\$100m to \$250m	\$250m to \$500m	\$500m to \$1bn	Greater than \$1bn			
Accounting	0.8	1.1	1.7	1.4	2.4			
Legal	1.4	2.0	2.6	3.1	3.0			
Printing	0.3	0.4	0.6	0.6	0.7			
Other*	0.5	0.7	1.7	1.0	2.7			
Underwriting	4.3	10.3	20.5	35.6	61.4			
Total Avg IPO cost	7.3	14.4	27.0	41.4	70.3			

*Other costs include costs like SEC registration, market listing fees and other miscellaneous costs

Costs were taken from SEC filings for US IPOs on major exchanges from January 2015 – September 2017. We have excluded IPOs that were best efforts, under \$25 million, special purpose acquisition companies (SPACs), dual listings or domestic market uplistings. We have also excluded Health Services IPOs due to sample size. Total IPOs reviewed: 315

¹ PWC

Issues to Consider in Advance of IPO Kick-off Meeting

- Upgrade internal controls, including Sarbanes-Oxley compliance, to ensure integrity of financial statements and sound corporate governance
 - GAAP compliant
 - Critical accounting policies
- Preparation of due diligence materials, including capitalization table review
- Prepare fact book to support market data
- Consider whether IT systems sufficient for a public company

Issues to Consider in Advance of IPO Kick-off Meeting

- Independent external PCAOB-registered auditor
 - Conduct necessary audits of prior-year financial statements
- Repayment of officer and/or director loans
- Sufficiency of minute books and other corporate records
- Appropriate risk management and mitigation plans

Issues to Consider in Advance of IPO Kick-off Meeting

- Directors and officers' insurance and understand required IPO upgrades
- Selection of independent directors for Board of Directors
- Consider any required upgrades to management team
- Review compensation programs and past equity awards SEC rules require detailed disclosure and analysis of compensation programs

IPO Working Group

- Management, including financial reporting team
- Company counsel
- Investor relations
- Managing underwriters
- Underwriters' counsel
- Auditors
- Transfer agent
- Financial printer

Issues to Consider in Choosing Managing Underwriters

- Firm's knowledge of, and expertise in, your industry
 - Recent transactions
 - Aftermarket performance
- Resource commitment (during and after the transaction)
 - Investment banking team experience with similar companies
 - Research analyst
 - Distribution Capabilities institutional versus retail
 - Market making activities

Issues to Consider in Choosing Managing Underwriters

- Research positioning in your industry
 - Research analyst's reputation
 - Current coverage universe
- Valuation, structure and timing
 - Approach to valuation
 - Transaction terms (see "Structure of Offering" below)
 - Filing strategy/pricing strategy
 - Recommendation on timing

Issues to Consider in Choosing Managing Underwriters

- Proposed spread and other underwriters' compensation matters
- Recommended selling strategy
 - Institutional vs. retail
 - Domestic vs. international
 - Road show recommendations

Your CLE Credit Information

For <u>ALL</u> attorneys seeking CLE credit for attending this webinar, please write down the alphanumeric code on the right >>

Kindly insert this code in the **pop-up survey** that will appear in a new browser tab after you exit out of this webinar.



Structure of Offering

- Offering size
 - Primary
 - Selling shareholders, if any
 - Over-allotment option (size and split between company and any selling shareholders)
- Consider implementation of dual class Common Stock
- Tax implications (e.g., UP-C IPO structure)
- Use of proceeds

Structure of Offering

- Syndicate strategy
- Shares to be reserved for specific investors or syndicate members
- Underwriter compensation anticipated discount from price to public
- Road show
- Nasdaq/New York Stock Exchange listing
- Ticker Symbol preference (reserve in advance)
- Directed Share Program
- JOBS Act Review Emerging Growth Company disclosure options and determine disclosure regime

Directors

- Composition of board after offering a majority of independent directors are required, best to ensure compliance by IPO effectiveness
- Diversity considerations
- Board committees, including audit and compensation committees with at least 3 independent directors within one year after IPO, best to ensure compliance by IPO effectiveness
- Analyze impact if controlled company
- Director compensation arrangements
 - Cash compensation
 - Equity compensation
 - Committee compensation
- Audit Committee financial expert

Employees

- Non-compete arrangements, non-solicitation and confidentiality arrangements
- Incentive arrangements and plans

Directors and officers' liability insurance

- Coverage amount
- Entity coverage
- Cost
- Breadth of coverage
- Deductibles

Corporate structure

- Charter and bylaws review and make any necessary changes
 - Review capital structure (make sure that there will be sufficient common stock and blank check preferred, high-vote/low-vote classes of stock)
 - Antitakeover provisions, such as consideration of a classified board, frequency of director elections, blank check preferred and poison pill
 - Consider other shareholder issues, such as special meeting, written consent, exclusive forum provisions
 - Remove any unnecessary provisions
 - Review indemnification provisions

Corporate structure

- Review corporate structure
 - Consider merging subsidiaries prior to offering
 - Tax issues
- Corporate records
 - Review minute books for completeness and accuracy

Corporate Structure

- Share capital
 - Review existing shareholder list
 - Registration rights/waivers
 - Lock-ups
 - Existing lock-ups required by financing agreements
 - ii. Requests for new lock-ups
 - iii. Lock-ups in option agreements

Corporate Structure

- Share Capital
- Preemptive rights; antidilution provisions
- Accuracy and completeness of stock books
- Possible bank change-in-control issues (large shareholders)
- Identify all issuances of compensatory equity since formation and confirm Rule 701 compliance
- Shares authorized and outstanding amend charter as necessary
- Transition stock recordkeeping to transfer agent
- Stock options outstanding and equity awards to be granted

Corporate Governance

- Prepare new Board Committee charters (should be adopted pre-IPO to ensure compliance with applicable listing and SEC rules and regulations)
- Prepare Code of Conduct, including Code of Ethics
- Prepare Insider Trading Policy
- Prepare/consider Whistleblower Policy, Related Party Transactions Policy, Regulation FD Compliance Program, Clawback Policy, Anti-Corruption Policy
- Prepare D&O Questionnaire Form
- Stock ownership guidelines and requirements (if any) for directors and executives

- Outstanding claims resolve if practical to do so
- Third-party consents
- Disclosure issues
 - Confidentiality agreement restrictions
 - Material contracts
 - i. Identify
 - ii. Disclosure issues
 - iii. Exhibits to registration statement
 - iv. Confidential treatment (consider redactions)

- Disclosure issues
 - Related party transactions
 - i. Identify
 - ii. Consider if advantageous to continue
 - iii. Consider need for new related party agreements
 - iv. Ratification by independent directors
 - Status of IP and any infringement issues
 - Employment agreements
 - Management compensation

- Disclosure issues
 - Equity grants to executive officers
 - Pending acquisitions or other material transactions
 - Restrictions on future activity contained in commercial agreements
 - Antitakeover provisions

- D&O Questionnaires Identify any issues raised by responses
- Make sure that there is appropriate trademark protection for the Company's name and that there are no other intellectual property conflicts
- Regularly review website for "gun jumping" issues
- Establish history of ordinary course business and financial communications
- Blue sky matters most likely not an issue
- Review FINRA affiliations, if any

Accounting and Financial Issues

- Preparation and audit of financial statements for an emerging growth company only two years is required – however, discuss marketing needs with underwriters
- Need for unaudited interim financial statements SAS review by auditors
- Historical option pricing or other cheap stock issues 12-month look back; transition to 6-month (or more frequent) 409A valuations
- Historical revenue recognition policy
- Management's Discussion and Analysis of Financial Condition and Results of Operation

Morgan Lewis

Accounting and Financial Issues

- Comfort letter from auditors to underwriters
- Management letters
- Availability and discussion of forecast information
- Pro forma presentations
- Risk factor disclosure

Interaction with Public During Offering Process; Publicity

- Prior to filing; registration period; post effectiveness
- Filing press release Rules 135, 134
- Employee communications
- Web page communications
- Analyst and investor meetings
- Public relations firm
- Communications with existing investors

Post-Offering Issues for Underwriters

- Continuing market making
- Provision of research reports
- Follow-on offering
- M&A Services

Coronavirus COVID-19 Resources


We have formed a multidisciplinary **Coronavirus/COVID-19 Task Force** to help guide clients through the broad scope of legal issues brought on by this public health challenge.

To help keep you on top of developments as they unfold, we also have launched a resource page on our website at www.morganlewis.com/topics/coronavirus-covid-19

If you would like to receive a daily digest of all new updates to the page, please visit the resource page to subscribe using the purple "Stay Up to Date" button.



Biography



Bryan Keighery
Boston, MA
+1.617.341.7269
bryan.keighery@morganlewis.com

Bryan S. Keighery represents life science and technology companies in a range of corporate and securities transactions. He handles a variety of corporate finance transactions for public companies, including initial public offerings, follow-on offerings, registered direct offerings (RDOs), and private investments in public equity (PIPEs), as well as venture capital and other financing transactions for privately held companies. Additionally, Bryan counsels both public and privately held companies on general corporate law, mergers and acquisitions, and other business matters.

Bryan also regularly counsels public companies in annual, quarterly, and periodic reports; proxy statements and SEC compliance under US federal securities laws; and corporate governance requirements of various stock exchanges, including NYSE and Nasdaq.

Biography



Thurston J. Hamlette
New York, NY
+1.212.309.6240
thurston.hamlette@morganlewis.com

Thurston J. Hamlette focuses his practice on corporate and securities matters, primarily representing issuers and investment banks in public and private corporate finance transactions. His experience encompasses registered offerings of debt and equity securities, Rule 144A and Regulation S transactions, high-yield and investment grade debt offerings, follow-on and secondary equity offerings, initial public offerings, special purpose acquisition companies (SPACs), and liability management transactions. In addition, Thurston counsels on securities law compliance, public company reporting, corporate governance, and other general corporate matters.

Our Global Reach

Africa Latin America Asia Pacific Middle Fast North America Europe

Our Locations

Abu Dhabi New York Nur-Sultan Almaty **Orange County** Beijing*

Boston Paris

Brussels Philadelphia **Century City** Pittsburgh Chicago Princeton Dallas San Francisco

Dubai Seattle Frankfurt Shanghai* Hartford Silicon Valley Hong Kong* Singapore* Houston Tokyo

London Washington, DC

Los Angeles Wilmington

Miami



Morgan Lewis

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan, Lewis & Bockius is a separate Hong Kong general partnership registered with The Law Society of Hong Kong. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

THANK YOU

- © 2023 Morgan, Lewis & Bockius LLP
- © 2023 Morgan Lewis Stamford LLC
- © 2023 Morgan, Lewis & Bockius UK LLP

Morgan, Lewis & Bockius UK LLP is a limited liability partnership registered in England and Wales under number OC378797 and is a law firm authorised and regulated by the Solicitors Regulation Authority. The SRA authorisation number is 615176.

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan, Lewis & Bockius is a separate Hong Kong general partnership registered with The Law Society of Hong Kong. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

This material is provided for your convenience and does not constitute legal advice or create an attorney-client relationship. Prior results do not guarantee similar outcomes. Attorney Advertising.